We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
24 result(s) found, displaying 11 to 20
-
Australian public assessment report (AusPar)Minjuvi (tafasitamab) is provisionally approved for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplants.
-
Designation or determinationOrphan drug
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PEMAZYRE pemigatinib 9 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PEMAZYRE pemigatinib 4.5 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PEMAZYRE pemigatinib 13.5 mg tablet blister pack.
-
Australian public assessment report (AusPar)AusPAR for Pemazyre (pemigatinib) for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or rearrangement that has progressed after at least one prior line of systemic therapy.
-
Prescription medicine decision summaryWe have approved Minjuvi (tafasitamab) to treat diffuse large B-cell lymphoma (DLBCL).
-
Prescription medicine registrationActive ingredients: tafasitamab.
-
Prescription medicine decision summaryTGA decision: Pemazyre (pemigatinib) is approved to treat cancer
-
Prescription medicine registrationActive ingredients: pemigatinib.